Home » Stocks » ZNTL

Zentalis Pharmaceuticals, Inc. (ZNTL)

Stock Price: $49.13 USD -1.79 (-3.52%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 2.00B
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 37.96M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $49.13
Previous Close $50.92
Change ($) -1.79
Change (%) -3.52%
Day's Open 50.60
Day's Range 48.41 - 51.77
Day's Volume 287,522
52-Week Range 23.20 - 57.97

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GuruFocus - 1 month ago

Andreas Halvorsen (Trades, Portfolio) has revealed a reduction in his holding of Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL), according to GuruFocus' Real-Time Picks, a Premium feature.

GlobeNewsWire - 2 months ago

NEW YORK and SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small ...

GlobeNewsWire - 4 months ago

Live webcast to be held on September 24th at 12:00 p.m. EDT Live webcast to be held on September 24th at 12:00 p.m. EDT

GlobeNewsWire - 4 months ago

NEW YORK and SAN DIEGO, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing sma...

GlobeNewsWire - 5 months ago

Closed initial public offering (IPO) of common stock, raising gross proceeds of ~$190.0 million Raised an additional ~$144.4 million in gross proceeds from recent follow-on offering Comple...

GlobeNewsWire - 5 months ago

NEW YORK and SAN DIEGO, July 29, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing smal...

GlobeNewsWire - 5 months ago

NEW YORK and SAN DIEGO, July 27, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing smal...

GlobeNewsWire - 5 months ago

NEW YORK & SAN DIEGO, July 27, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small ...

GlobeNewsWire - 6 months ago

NEW YORK and SAN DIEGO, July 01, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing smal...

CNN Business - 6 months ago

Health care companies and governments are racing to find a vaccine or other effective treatment for Covid-19 -- so investors have been piling into stocks like Gilead Sciences, Moderna and Nova...

Other stocks mentioned: BIO, FMTX, IMRA, KROS, PCVX, RNA, RPTX, XBI
GlobeNewsWire - 7 months ago

NEW YORK and SAN DIEGO, June 15, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing smal...

The Motley Fool - 7 months ago

The company's share price has nearly tripled since its IPO less than two months ago. Is it too late to get in on the fun?

GlobeNewsWire - 7 months ago

NEW YORK, SAN DIEGO and DURHAM, N.C., May 28, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) and Tavros Therapeutics, Inc., today announced a strategic collaboration ...

GlobeNewsWire - 7 months ago

Zentera will be the sole licensee of three Zentalis discovered therapies for development and commercialization in China Zentera will be the sole licensee of three Zentalis discovered therapies...

GlobeNewsWire - 7 months ago

Zentera will be the sole licensee of three Zentalis discovered therapies for development and commercialization in China Zentera will be the sole licensee of three Zentalis discovered therapies...

GlobeNewsWire - 8 months ago

Completed initial public offering of common stock, raising approximately $190.0 million in gross proceeds

GlobeNewsWire - 8 months ago

ZN-d5 is the Company’s fourth product candidate to receive IND clearance in five years ZN-d5 is the Company’s fourth product candidate to receive IND clearance in five years

The Motley Fool - 8 months ago

These companies just raised significant cash to advance promising drug pipelines.

Other stocks mentioned: KROS
Seeking Alpha - 9 months ago

Biotech pharmaceutical company Zentalis Pharmaceuticals has launched a successful IPO that values the company at over $730 million.

About ZNTL

Zentalis Pharmaceuticals, a clinical-stage biopharmaceutical company, develops small molecule therapeutics for the treatment of various cancers in the United States. Its lead product candidate is the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase I/II clinical trial for the treatment of advanced or metastatic breast cancer. The company also develops ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase I/II clinical trial for the treatment of advanced solid tumors; ZN-d5, a selective inhibitor of B-ce... [Read more...]

Industry
Biotechnology
IPO Date
Apr 3, 2020
CEO
Dr. Anthony Y. Sun M.D.
Employees
110
Stock Exchange
NASDAQ
Ticker Symbol
ZNTL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for ZNTL stock is "Strong Buy." The 12-month stock price forecast is 57.00, which is an increase of 16.02% from the latest price.

Price Target
$57.00
(16.02% upside)
Analyst Consensus: Strong Buy